A. Marshall

发表

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.

S. Pinder, H. Earl, D. Rea, 2016, Journal of the National Cancer Institute.

Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer

J. Donovan, S. Pinder, D. Rea, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial

S. Pinder, A. Makris, J. Bartlett, 2017, British Journal of Cancer.

OPTIMA: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

J. Donovan, S. Pinder, A. Makris, 2016 .

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.

John M S Bartlett, Christopher McCabe, Nigel Stallard, 2016, Health technology assessment.

A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines

A. Marshall, J. Dunn, P. Mistry, 2017, BMC Medical Research Methodology.

Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial

J. Harvey, C. Kirwan, A. Marshall, 2020, Trials.

Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial

D. Rea, C. Poole, I. Ahmed, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The potential utility of abbreviated breast MRI (FAST MRI) as a tool for breast cancer screening: a systematic review and meta-analysis.

M. Halling-Brown, R. Sidebottom, S. Taylor-Phillips, 2020, Clinical radiology.

A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update

P. Lorigan, A. Marshall, J. Dunn, 2008, Ecancermedicalscience.

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

G. Lyman, F. Hobbs, A. Maraveyas, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

H. Earl, D. Rea, J. Yarnold, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

University of Birmingham Strategies to improve recruitment to a de-escalation trial

L. Hughes-Davies, A. Marshall, J. Dunn, 2020 .

Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis.

P. Bossuyt, H. Büller, T. Zemla, 2020, Blood.

Evaluating the effectiveness of abbreviated breast MRI (abMRI) interpretation training for mammogram readers: a multi-centre study assessing diagnostic performance, using an enriched dataset

C. Kuhl, M. Halling-Brown, R. Sidebottom, 2022, Breast cancer research : BCR.

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial

P. Lorigan, A. Marshall, J. Dunn, 2018, British Journal of Cancer.

sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients

Stephen M. Douglass, A. Weeraratna, Xiaowei Xu, 2020, Clinical Cancer Research.

SELECT-D: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism.

A. Marshall, J. Dunn, A. Young, 2014 .

Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism : results of the 'select-d' Pilot Trial

A. Marshall, J. Dunn, M. Levine, 2018 .

Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial

A. Marshall, J. Dunn, M. Levine, 2017 .

Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m)

F. Hobbs, A. Maraveyas, A. Marshall, 2020, Journal of thrombosis and haemostasis : JTH.

Neo-escape: Neoadjuvant extended sequential chemotherapy with adjuvant postoperative treatment for epithelial nonmucinous advanced inoperable peritoneal malignancy.

C. Poole, A. Marshall, J. Dunn, 2012 .

Cabazitaxel in Platinum Pre-treated Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression after Platinum based Chemotherapy: Results of the Phase II CAB-B1 Trial

N. James, A. Zarkar, A. Marshall, 2019, International Journal of Cancer Research & Therapy.

Radical treatment of muscle-invasive bladder cancer—are options equal?

A. Zarkar, A. Marshall, J. Dunn, 2018, Journal of Radiation Oncology.

Synchronous versus sequential chemoradiotherapy in patients with early stage breast cancer (SECRAB)

D. Rea, C. Poole, I. Ahmed, 2020 .

COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.

D. Cunningham, J. Bridgewater, S. Madhusudan, 2013 .

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. Dziewulski, M. Gore, M. Highley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

aTTom (adjuvant Tamoxifen--To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer--Preliminary results

H. Earl, R. Gray, C. Poole, 2008 .

Assessing violations of the proportional hazards assumption in Cox regression: does the chosen method matter?

A. Marshall, J. Dunn, L. Hiller, 2015, Trials.

Outcome of T1N0M0 squamous cell carcinoma of the larynx treated with short-course radiotherapy to a total dose of 50 Gy in 16 fractions: the Birmingham experience.

A. Marshall, A. Hartley, J. Glaholm, 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

Follow-up in early breast cancer--a surgical and radiological perceptive.

M. Wilcox, A. Marshall, J. Dunn, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone.

A. Padhani, D. Koh, A. Makris, 2020, Radiology.

Importance of protocols for simulation studies in clinical drug development

Andrea Marshall, Mike K Smith, Mike K. Smith, 2011, Statistical methods in medical research.

Can we afford to ignore missing data in cost-effectiveness analyses?

Stirling Bryan, Andrea Marshall, S. Bryan, 2009, The European Journal of Health Economics.

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

N. Dhomen, R. Marais, P. Lorigan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Intravenous high‐dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta‐analysis of three trials

H. Gogas, A. Marshall, G. Fountzilas, 2015, Cancer medicine.

ctDNA monitoring using patient-specific sequencing and integration of variant reads

N. Rosenfeld, C. Caldas, J. Abraham, 2020, Science Translational Medicine.

FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

A. deFazio, D. Brennan, A. Marshall, 2019, British Journal of Cancer.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

M. Gore, P. Nathan, P. Lorigan, 2014, The Lancet. Oncology.

Adaptive designs for clinical trials assessing biomarker-guided treatment strategies

N Stallard, A Marshall, J. Wason, 2014, British Journal of Cancer.

The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation

E. Provenzano, H. Earl, D. Rea, 2019, Journal of clinical epidemiology.

Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.

H. Earl, D. Rea, A. Makris, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

D. Cunningham, J. Bridgewater, S. Madhusudan, 2014, The Lancet. Oncology.

Patient, health service factors and variation in mortality following resuscitated out-of-hospital cardiac arrest in acute coronary syndrome: Analysis of the Myocardial Ischaemia National Audit Project.

G. Perkins, C. Gale, A. Marshall, 2018, Resuscitation.

Variation in outcome of hospitalised patients with out-of-hospital cardiac arrest from acute coronary syndrome : a cohort study

G. Perkins, C. Gale, A. Marshall, 2018 .

Can mammogram readers swiftly and effectively learn to interpret first post-contrast acquisition subtracted (FAST) MRI, a type of abbreviated breast MRI?: a single centre data-interpretation study.

S. Taylor-Phillips, A. Marshall, J. Dunn, 2019, The British journal of radiology.

OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism.

A. Marshall, J. Dunn, A. Young, 2016, Thrombosis research.

Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta‐analysis

W. Ageno, A. Marshall, A. Delluc, 2021, Journal of thrombosis and haemostasis : JTH.

First UK patient cohort treated with stereotactic ablative radiotherapy for primary kidney cancer

A. Zarkar, A. Marshall, A. Carver, 2023, BJUI compass.

FKBPL: a marker of good prognosis in breast cancer

I. Ellis, A. Green, E. Rakha, 2015, Oncotarget.

A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients

A. Carmichael, A. Marshall, J. Dunn, 2020, Breast Cancer Research and Treatment.

Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data

S. Park, A. Marshall, J. Dunn, 2016, British Journal of Cancer.

Consolidated criteria for reporting qualitative research guidelines

J. Donovan, S. Pinder, A. Makris, 2016 .

The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial

A. Marshall, J. Dunn, C. Hulme, 2015, PharmacoEconomics.

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.

M. Gore, P. Nathan, P. Lorigan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cougar-02 : a randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma

D. Cunningham, J. Bridgewater, S. Madhusudan, 2013 .

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial

P. Lorigan, A. Marshall, J. Dunn, 2018, British Journal of Cancer.

High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads

N. Rosenfeld, G. Bignell, C. Parkinson, 2019, bioRxiv.

Abstract P4-11-07: Comparison of multiparameter tests in the UK OPTIMA-Prelim trial

J. Donovan, S. Pinder, A. Makris, 2015 .

Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer

J. Donovan, S. Pinder, H. Earl, 2015 .

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

G. Lyman, F. Hobbs, A. Maraveyas, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

D. Cunningham, J. Bridgewater, S. Madhusudan, 2014, The Lancet. Oncology.

Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.

B. Kiely, D. Rea, B. Naume, 2021 .

OPTIMA (Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.

S. Pinder, H. Earl, D. Rea, 2016 .

FKBPL: a marker of good prognosis in breast cancer

I. Ellis, E. Rakha, J. Bartlett, 2015, Oncotarget.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

M. Gore, A. Dalgleish, P. Nathan, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.